 | Zacks: Analysts Expect Incyte Co. (NASDAQ:INCY) Will Post Earnings of $0.65 Per Share
www.americanbankingnews.com - October 21 at 3:18 AM |
 | Innovent Biologics Announces Positive Updated Result from the Incyte-sponsored Phase II Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma
www.prnewswire.com - October 20 at 8:30 PM |
| Innovent Biologics Announces Positive Updated Result from the Incyte-sponsored Phase II Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma - PRNewswire
www.prnewswire.com - October 20 at 8:17 PM |
 | Why the Earnings Surprise Streak Could Continue for Incyte (INCY) - Yahoo Finance
finance.yahoo.com - October 18 at 12:50 PM |
| Why the Earnings Surprise Streak Could Continue for Incyte (INCY)
finance.yahoo.com - October 18 at 12:50 PM |
| Incyte Co. Forecasted to Earn Q3 2019 Earnings of $0.42 Per Share (NASDAQ:INCY)
www.americanbankingnews.com - October 18 at 6:41 AM |
| Novartis' Jakavi Meets Primary Goal in Phase III for GVHD
finance.yahoo.com - October 17 at 1:38 PM |
 | Incyte (INCY) Reports REACH2 Pivotal Trial of Ruxolitinib (Jakafi) Meets Primary Endpoint - StreetInsider.com
www.streetinsider.com - October 16 at 7:48 AM |
 | Incyte rerpots positive results in late-stage trial of treatment for GVHD - MarketWatch
www.marketwatch.com - October 16 at 7:48 AM |
| Incyte Announces that the REACH2 Pivotal Trial of Ruxolitinib (Jakafi®) Meets Primary Endpoint in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease
finance.yahoo.com - October 16 at 7:48 AM |
| Incyte rerpots positive results in late-stage trial of treatment for GVHD
finance.yahoo.com - October 16 at 7:48 AM |
| Were Hedge Funds Right About Dumping Incyte Corporation (INCY)? - Yahoo Finance
finance.yahoo.com - October 15 at 7:03 PM |
| Were Hedge Funds Right About Dumping Incyte Corporation (INCY)?
finance.yahoo.com - October 15 at 7:03 PM |
 | Incyte's ruxolitinib cream shows sustained benefit in mid-stage vitiligo study - Seeking Alpha
seekingalpha.com - October 15 at 4:00 AM |
| Mizuho Securities Reiterates Buy Rating on Incyte (INCY) - StreetInsider.com
www.streetinsider.com - October 14 at 2:10 PM |
| Is Incyte Corporation's (NASDAQ:INCY) CEO Pay Justified? - Yahoo Finance
finance.yahoo.com - October 14 at 2:10 PM |
| Incyte (INCY) Reports Positive 52-Wk Results From a Randomized Phase 2 Study of Ruxolitinib Cream in Patients With Vitiligo - StreetInsider.com
www.streetinsider.com - October 14 at 8:58 AM |
| Incyte Co. (NASDAQ:INCY) Short Interest Update
www.americanbankingnews.com - October 12 at 7:47 PM |
 | Incyte Announces Positive 52-Week Results From a Randomized Phase 2 Study of Ruxolitinib Cream in Patients With Vitiligo - Business Wire
www.businesswire.com - October 12 at 1:57 PM |
| Incyte Announces Positive 52-Week Results From a Randomized Phase 2 Study of Ruxolitinib Cream in Patients With Vitiligo
www.businesswire.com - October 12 at 5:16 AM |
 | bluebird Inks Genome Editing Research Deal With Novo Nordisk - Nasdaq
www.nasdaq.com - October 10 at 6:35 PM |
| bluebird Inks Genome Editing Research Deal With Novo Nordisk - Yahoo Finance
finance.yahoo.com - October 10 at 1:34 PM |
| bluebird Inks Genome Editing Research Deal With Novo Nordisk
finance.yahoo.com - October 10 at 1:34 PM |
| Incyte to Report Third Quarter Financial Results - Business Wire
www.businesswire.com - October 10 at 8:34 AM |
| Incyte to Report Third Quarter Financial Results
finance.yahoo.com - October 10 at 8:33 AM |
| BriaCell Therapeutics Corp. to File Amendment to Management Information Circular - Yahoo Finance
finance.yahoo.com - October 8 at 11:05 PM |
| Lilly to Unveil New Data for the Treatments of Complex Dermatological Conditions at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress
finance.yahoo.com - October 8 at 8:01 AM |
| BriaCell Doses First Patient in Phase I/IIa Study Evaluating Bria-IMT™ in Combination with INCMGA00012 and Epacadostat in Patients with Advanced Breast Cancer - Yahoo Finance
finance.yahoo.com - October 7 at 1:44 PM |
 | BriaCell Doses First Patient in Phase I/IIa Study Evaluating Bria-IMT™ in Combination with INCMGA00012 and Epacadostat in Patients with Advanced Breast Cancer - GlobeNewswire
www.globenewswire.com - October 7 at 8:44 AM |
 | 3 Drug Stocks Poised for Gains After Cancer Conference - Investopedia
www.investopedia.com - October 4 at 3:39 PM |
| Incyte Sees Hammer Chart Pattern: Time to Buy? - Yahoo Finance
finance.yahoo.com - October 4 at 3:39 PM |
| Incyte Sees Hammer Chart Pattern: Time to Buy?
finance.yahoo.com - October 4 at 8:32 AM |
| Is Incyte (INCY) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
finance.yahoo.com - October 3 at 5:32 PM |
| Bausch Files Lawsuit Against Novartis' Sandoz, Shares Down
finance.yahoo.com - October 3 at 5:31 PM |
| Incyte (NASDAQ:INCY) Now Covered by Analysts at Mizuho
www.americanbankingnews.com - October 2 at 10:53 PM |
| Mizuho Securities Starts Incyte (INCY) at Buy - StreetInsider.com
www.streetinsider.com - October 2 at 8:50 PM |
| Incyte (NASDAQ:INCY) PT Set at $101.00 by Guggenheim
www.americanbankingnews.com - September 30 at 8:20 PM |
| Incyte's (INCY) Buy Rating Reiterated at Cowen
www.americanbankingnews.com - September 30 at 7:20 PM |
| Incyte Corp.: Maybe The Next Netflix - Seeking Alpha
seekingalpha.com - September 30 at 3:58 PM |
| Incyte (INCY) Presents At ESMO Congress 2019 - Slideshow
seekingalpha.com - September 30 at 1:18 PM |
| Incyte (NASDAQ:INCY) PT Raised to $110.00 at JMP Securities
www.americanbankingnews.com - September 30 at 10:20 AM |
 | The 3 Best Health-Care Stocks This Month. And the Worst - Barron's
www.barrons.com - September 30 at 8:11 AM |
| $540.90 Million in Sales Expected for Incyte Co. (NASDAQ:INCY) This Quarter
www.americanbankingnews.com - September 30 at 2:59 AM |
| Incyte on go with U.S. application for pemigatinib in bile duct cancer in Q4
seekingalpha.com - September 29 at 5:01 PM |
| Zacks: Brokerages Expect Incyte Co. (NASDAQ:INCY) to Announce $0.50 EPS
www.americanbankingnews.com - September 28 at 12:21 PM |
| Incyte (INCY) Stock Up 16% YTD on Strong Jakafi Performance - Yahoo Finance
finance.yahoo.com - September 27 at 9:15 PM |
| Incyte Announces Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma - StreetInsider.com
www.streetinsider.com - September 27 at 4:15 PM |
| Incyte (INCY) Reports Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients - StreetInsider.com
www.streetinsider.com - September 27 at 8:09 AM |
| Incyte Announces Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma - Business Wire
www.businesswire.com - September 27 at 8:09 AM |
| Incyte Announces Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma
finance.yahoo.com - September 27 at 8:09 AM |
